Metrics as of 10/16/2026, 03:03 PM (Berlin time), refresh in progress.
Inhibikase Therapeutics Stock
Inhibikase Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mark T. Iwicki
- Employees
- 35
- Market cap
- $255 M
- IPO
- 23/12/2020
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and…
Inhibikase Therapeutics stock: price history
1D
+1.7%
1W
-4.2%
1M
-20.8%
6M
+7.6%
YTD
-10.7%
1Y
+14.4%
2Y
+7.0%
5Y
-84.2%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~11% weaker price swings than usual
Inhibikase Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Inhibikase Therapeutics is a clinical-stage pharmaceutical company specializing in the development of therapeutics for cardiopulmonary diseases, with a focus on treating pulmonary arterial hypertension (PAH). The lead program is IKT-001, an oral prodrug of imatinib mesylate, designed to minimize gastrointestinal tolerability issues while maintaining high efficacy. The compound is currently being evaluated in a global Phase 3 trial to assess its efficacy and safety.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Inhibikase Therapeutics
Analyst assessment of Inhibikase Therapeutics
PRICE TARGET LOW
US$1.50
CONSENSUS
US$4.83
MEDIAN
US$5.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
0
BUY
2
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Hold
As of: 28/03/2025
Inhibikase Therapeutics stock metrics
P/E
-3.85
P/B
2.08
EV/EBITDA
-3.6
RETURN ON EQUITY
-12.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
122.4%
FLOAT SHARES
170,737,522
AVG. DAILY VOLUME (30D)
604,194
Insider transactions (SEC)
BERMAN DENNIS N
RA CAPITAL MANAGEMENT, L.P.
Attention
Price since yesterday: +1.7%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Inhibikase Therapeutics stock
What does Inhibikase Therapeutics do?
Inhibikase Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mark T. Iwicki, the company employs around 35 people.
The IPO was on 23/12/2020; the stock trades on NASDAQ under the ticker IKT.
What do analysts say about Inhibikase Therapeutics stock?
2 analysts rate the stock, the consensus is Hold (as of 28/03/2025).
The average price target is US$4.83, ranging from US$1.50 to US$8.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Inhibikase Therapeutics report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Inhibikase Therapeutics pay a dividend?
No, Inhibikase Therapeutics currently does not pay a dividend.
Which stocks are comparable to Inhibikase Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Inhibikase Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Inhibikase Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.